Skip to main content
AM

Aqua Medical

Aqua Medical has developed a through-the-endoscope Radio Frequency Vapor Ablation (RFVA) system that utilizes heated water vapor to non-surgically ablate the duodenal mucosa, aiming to improve glycemic control in patients with type 2 diabetes. This outpatient procedure offers a 30-minute treatment option that may help patients achieve and maintain targeted HbA1c levels, potentially reducing the economic burden on the healthcare system.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Type 2 diabetes is a widespread and growing global health concern, with numerous patients struggling to achieve and maintain target HbA1c levels despite the availability of over 50 pharmacologic therapies. Current medical management approaches often address symptoms without altering the underlying disease progression, potentially leading to increased insulin dependency and associated weight gain.

Solution

Aqua Medical offers a non-pharmacologic intervention for type 2 diabetes through a through-the-endoscope Radio Frequency Vapor Ablation (RFVA) system. This outpatient procedure involves a 30-minute ablation of the duodenal mucosa using heated water vapor delivered via a radiofrequency generator. The RFVA system aims to improve glycemic control by addressing the metabolic consequences of type 2 diabetes, potentially breaking the cycle of insulin dependency and weight gain. Aqua Medical's technology is designed as a platform, with a single RF vapor generator system and multiple unique catheters capable of delivering treatment for diseases throughout the GI tract.

Target Audience

The primary target audience includes physicians specializing in gastroenterology and endocrinology who seek alternative or adjunctive therapies for patients with type 2 diabetes.

Features

  • Through-the-endoscope delivery of heated water vapor for duodenal mucosa ablation.
  • Radiofrequency generator system for precise vapor creation and delivery.
  • Short, 30-minute outpatient procedure.
  • Potential to improve glycemic control and reduce HbA1c levels.
  • Platform technology adaptable for various GI applications with different catheters.
This profile is AI-generated and may contain inaccuracies.